Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE8H1W
|
|||
| Drug Name |
Aglatimagene besadenovec
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 3 | [2] | ||
| Malignant glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 2 | [3] | ||
| Pediatric glioma [ICD-11: 2A00.0] | Phase 2 | [2] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1/2 | [2] | ||
| Malignant pleural effusion [ICD-11: 2D72; ICD-10: C78.2; ICD-9: 511.81] | Phase 1 | [2] | ||
| Company |
Advantagene
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03313596) Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT00589875) Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.